GILD stock forecast
Our latest prediction for Gilead Sciences, Inc.'s stock price was made on the Feb. 28, 2018 when the stock price was at 78.73$.
In the short term (2weeks), GILD's stock price should outperform the market by 0.12%. During that period the price should oscillate between -3.90% and +3.66%.
In the medium term (3months), GILD's stock price should outperform the market by 0.90%. During that period the price should oscillate between -8.07% and +10.48%.Get email alerts
Create a solid portfolio with GILD
About Gilead Sciences, Inc.
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firms primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster, CA.
At the moment the company generates 22365M USD in revenues.
On its last earning announcement, the company reported a profit of 2.12$ per share.
The book value per share is 16.72$
Three months stock forecastFeb. 28, 2018
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|